Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
about
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderLevomilnacipran for the treatment of major depressive disorder: a reviewEfficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsThe efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled studyA double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorderTypology of patients with fibromyalgia: cluster analysis of duloxetine study patientsLevomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.Treatment of traumatised refugees with basic body awareness therapy versus mixed physical activity as add-on treatment: Study protocol of a randomised controlled trial.Development of the Global Disability Scale (Glo.Di.S): preliminary resultsImplementing a knowledge application program for anxiety and depression in community-based primary mental health care: a multiple case study research protocol.Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.A simple attention test in the acute phase of a major depressive episode is predictive of later functional remission.Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials.Trajectories of functioning after remission from anxiety disorders: 2-year course and outcome predictors.Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study.Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.Functioning, Disability, and Social Adaptation Six Months After Burn Injury.Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertralineSafety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxietyRelapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trialPsychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder
P2860
Q24564427-1C85B333-A508-4C58-9F20-0DDC0197CE7AQ28083216-41AF4A9B-2339-40E5-B369-7C3108A2C747Q33718213-330E440A-CE2F-4567-9637-C63015CF277AQ34531579-518D548F-A765-4D33-B81F-EC09C94EA236Q34630842-960EB58A-33FA-46BA-B4A6-8F18A36C9CB9Q35191443-22174AB7-CF86-4C65-98BE-A756BA7EC9CFQ36083249-EA05CF23-C36E-43F0-A5CC-0DA87BC946D8Q36168261-90E57F95-1377-42AD-97CC-97A11A6190CAQ36202904-77E04F74-4596-4DF7-ADBB-1D0876D768A5Q36209425-C576FF1D-69CD-44C2-B233-44E78E2985DBQ36735812-9D26C5DD-3B23-4FA9-B2C7-054BAD408242Q37308842-5737B999-ECDD-4286-9519-2875B74DAE18Q37404814-EE3BB94F-E261-40A6-A9B7-38F267CB1CC3Q37694366-35669F6C-302C-4DA5-B67B-C4847C8EBE07Q38249999-3EDD8F9D-ABAD-4163-A7B5-64D4104F4B68Q39298913-9C613D54-CEB9-47AB-ABD8-0459EDF031D3Q40665191-E102D091-2D1B-4E09-A1B3-9043771894E8Q45826307-73CF608A-1955-4D4B-AFC8-D2C6E785DD97Q47107468-DAD08A5E-242B-4F6B-8CFA-88C0ED7099C2Q47599068-4DD4B82D-BEDF-4CC8-81B1-A1FC3657C850Q48081024-6EFCF7C4-C10F-4FB8-BF76-A4BA845685ADQ57491808-5295B20E-365F-42FC-A233-DE5F636A86BCQ58781967-1E0E3845-D9AF-4214-9086-2EE1FAB723A8Q59128329-9204AFB5-83F9-4DDC-9F7B-9E96DECEB3EEQ59135361-8248F7C5-FC6E-4385-97E4-74A4FC0602D3
P2860
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Assessing remission in major d ...... the Sheehan disability scale.
@en
Assessing remission in major d ...... the Sheehan disability scale.
@nl
type
label
Assessing remission in major d ...... the Sheehan disability scale.
@en
Assessing remission in major d ...... the Sheehan disability scale.
@nl
prefLabel
Assessing remission in major d ...... the Sheehan disability scale.
@en
Assessing remission in major d ...... the Sheehan disability scale.
@nl
P2093
P1476
Assessing remission in major d ...... f the Sheehan disability scale
@en
P2093
Apurva Prakash
Harry F Thompson
Kathy Harnett-Sheehan
Melissa E Spann
P356
10.1097/YIC.0B013E328341BB5F
P577
2011-03-01T00:00:00Z